Antithyroid (ATD) Drug Study

Antithyroid drugs (ATDs) remain the primary treatment for a large proportion of patients with hyperthyroidism. However, about one in 500 of the approximately 15,000 new UK patients treated with ATDs each year will suffer a side effect. The ATD study is a 2 year national multi-centre study, led by the Royal Devon and Exeter NHS Foundation Trust and funded by the Clinical Endocrinology Trust (Registered charity number: 288679). The study will recruit 150 participants who have had a side effect, either in the past ten years or who suffer a side effect during the study.

The main study aims are to:

* Collect data to help us describe those who have suffered a side effect
* Find out how these side effects are treated across the UK
* Find out which treatments have better outcomes
* Collect DNA to see if we can find ways to predict who is at risk

To find historical cases we will look through hospital records and will then write to patients we feel could be eligible to join the study. In order to do this we have received approval from the Confidentiality Advisory Group (CAG) for England and Wales and the Public Benefit and Privacy Panel for Health and Social Care (PBPP) for Scotland, which are independent bodies that provide expert advice on the use of confidential patient information. For those who don’t wish to participate, we will delete their information.

For patients identified in clinics, information will be given to them, by hand, by their clinician.

**Our data processing impact assessment and fair processing of data notice can be found at Endocrinology.org**

If you have any questions or concerns about this study or the way in which we will identify and contact potential participants, please do not hesitate to get in touch with us at ATD.study@endocrinology.org.